Allergic disorders of the respiratory tract — findings from a large patient sample in the German statutory health insurance system

Biermann, Janine; Merk, Hans F.; Wehrmann, Wolfgang; Klimek, Ludger; Wasem, Jürgen

doi:10.1007/s15007-013-0350-6

Cited by 49 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, many medical societies and expert groups have recommended the use of AIT in selected individuals; this mainly covers patients with moderate‐to‐severe AR who either (i) do not gain sufficient relief from symptomatic medications or (ii) do obtain sufficient relief from symptomatic medications but consider that AIT may counter the severity of their AR symptoms and prevent progression to asthma . Despite these observations, levels of AIT acceptance (both by patients and physicians) are rather modest, as only a minority of eligible patients receive this treatment option …”

Section: Introductionmentioning

confidence: 99%

Clinical trials in allergen immunotherapy: current concepts and future needs

Pfaar

Alvaro

Cardona

et al. 2018

Allergy

View full text Add to dashboard Cite

Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested-primarily due to heterogeneity in clinical trial designs, study populations, therapeutic formulations, and efficacy criteria. After discussing current concepts and unmet needs, an This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical trials in allergen immunotherapy: current concepts and future needs

Pfaar

Alvaro

Cardona

et al. 2018

Allergy

View full text Add to dashboard Cite

show abstract

“…Healthy persons are usually adapted to the presence of bioaerosols in their natural environment. Bioaerosol exposure may represent an additional health risk, in particular for risk groups such as immunosuppressed persons or persons suffering from allergies or respiratory diseases (Biermann et al, 2013). In addition, it has to be considered that these risk groups comprise around one third of the population worldwide (Hauner, 2005;Hermann-Kunz and Thierfelder, 2001).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of exposure–response relationships for health effects of microbial bioaerosols – A systematic review

Walser¹,

Gerstner²,

Brenner³

et al. 2015

International Journal of Hygiene and Environmental Health

168

View full text Add to dashboard Cite

“…As a result, ever fewer physicians are performing allergy testing, as effectively demonstrated by the „Wasem study“ [18]. Thus, undiagnosed patients will also not receive allergen-specific therapy (i. e. allergen-specific immunotherapy).…”

Section: Discussionmentioning

confidence: 99%

“…In a treatment study commissioned by the Medical Association of German Allergologists (Ärzteverband Deutscher Allergologen, AeDA) and headed by Professor Dr. Jürgen Wasem from the chair of Medical Management at the University of Duisburg-Essen, a team of authors systematically analyzed over 40 million records of members of the German statutory health insurance with regard to the occurrence of allergic disease and the prescription of SIT [18]. Only 7 % of patients with AR and only 5 % of patients with allergic bronchial asthma received SIT [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Authorised allergen products for intracutaneous testing may no longer be available in Germany

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background:Beside the skin prick test, the intracutaneous test represents the most important skin test method for detecting type-1 allergies. With the incorporation of European directives into national law, test allergens used for allergy diagnosis are deemed medicinal products within the meaning of the German Medicinal Products Act (Arzneimittelgesetz) and therefore require marketing authorisation for distribution in Germany. The high costs of acquiring and maintaining these authorisations have lead to no new finished intracutaneous test products being authorized in Germany for more than 20 years. Instead, most manufacturers have voluntarily withdrawn their existing marketing authorisations for intracutaneous test extracts. The last manufacturer to offer approved finished allergen products for intracutaneous tests recently announced that it would now cease production and distribution of these solutions.Methods:Research on the current European and German legislation; selective literature search in Medline, including national and international guidelines and Cochrane meta-analyses; licensing information on the Paul-Ehrlich-Institute homepage (www.pei.de) as well as in the Bundesanzeiger (Federal Gazette).Results:According to information on www.pei.de, marketing authorisations still existed as of 31.01.2015 for intracutaneous test solutions of six grass/cereal/herbal pollens, seven tree pollens, ten food allergens, twelve moulds and yeasts as well as two fungal mixtures, five house dust and storage mites and five animal epithelia/danders, all held by only one company in Germany. These marketing authorisations were granted between 16th March 1987 and 17th January 1992; more recent marketing authorisations do not exist.Conclusions:European legislation and the associated increase in production and licensing costs have already lead to numerous suppliers withdrawing their marketing authorisation for diagnostic test allergens — marketing authorisations for 443 diagnostic allergens were voluntarily withdrawn by manufacturers in 2013 alone. If the announced restrictions on the allergen portfolio go ahead, considerable problems in the management of allergy patients in Germany due to the discontinuation of the intracutaneous test are likely to be encountered. Moreover, the fact that a diagnostic procedure that has been established for decades seems set to disappear quite simply because all the requisite substances vanish from the market in one fell swoop may well be without parallel in modern medicine.The situation for skin prick test allergens is less dramatic, although, here again, the available range is becoming increasingly limited.

show abstract

Allergic disorders of the respiratory tract — findings from a large patient sample in the German statutory health insurance system

Cited by 49 publications

References 21 publications

Clinical trials in allergen immunotherapy: current concepts and future needs

Clinical trials in allergen immunotherapy: current concepts and future needs

Evaluation of exposure–response relationships for health effects of microbial bioaerosols – A systematic review

Authorised allergen products for intracutaneous testing may no longer be available in Germany

Contact Info

Product

Resources

About